Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

NCT04676386 · clinicaltrials.gov ↗

TERMINATED

Status

29

Enrollment

OTHER

Sponsor class

Stopped Recruitment futility

Conditions

NSCLC Stage IV
NSCLC, Stage IIIC

Interventions

DIAGNOSTIC_TEST: Primary Immune Response (PIR) test by Biodesix, Inc.

Sponsor

Addario Lung Cancer Medical Institute

Collaborators

[object Object]